Blog
IEX Chromatography Leading the Charge in Charge Variant Analysis
BlogFind out how the biopharmaceutical industry has benefited from advances in chromatography technology, with insights from Matthew Lauber, consulting scientist at Waters.
Read More
Tailoring Flow Reactor Equipment to the Particular Chemistry at Hand
BlogWe recently spoke to André de Vries from InnoSyn BV to learn more about the considerations to make when scaling up chemical processes. He outlines the advantages of flow chemistry over batch processes and discusses how to design and manufacture flow reactors for any type of chemistry.
Read More
Take a Good Book Around
BlogOur recent social media poll on "book recommendations for scientists" provided an incredible response. We decided to collate this information and give you the perfect excuse to treat yourself to a new read. Enjoy!
Read More
The Vision for Multi-organ Human-on-a-Chip Models
BlogThe development of organ-on-a-chip models aims to reduce the (expensive) high drug failure rates that exist in clinical trials. A Florida biotech firm recently reported that their multi-organ “human-on-a-chip” system maintains cellular viability over 28 days in serum-free conditions, using a pumpless system. To learn more about the vision for multi-organ “human-on-a-chip” models, we caught up with James Hickman, Chief Science Officer of Hesperos Inc.
Read More
Is Off-the-Shelf Immunotherapy the Way Forward?
BlogAn “off-the-shelf” immuno-oncology product has been developed whereby T cells are derived from healthy donors, bypassing limitations related to high pricing and limited market access.
Read More
The Booming Business of Neurotoxin Therapy
BlogBotulinum neurotoxins are widely used in both therapeutic and cosmetic applications, but Ipsen says that their new rBoNT-E toxin is a step up from compounds based on the much more widely used serotype A toxin. We spoke to Ipsen Senior Vice President Neurosciences R&D, Philippe Picaut, to find out more.
Read More
Harnessing AI in a Battle Against Aging
BlogA recently announced collaboration between Juvenescence, Ltd., and NetraMark Corp. has yielded a new joint venture, NetraPharma, which aims to fight aging-related conditions. We spoke with NetraMark founder Dr. Joseph Geraci to find out more about how the process of targeting and treating neurodegenerative disorders will be radically changed by AI.
Read More
Biosimilar Surge Driving Need for Antibody Characterization
BlogAccurate protein characterization is particularly important in the biopharmaceutical industry, where product modifications can affect efficacy and safety. Here, we speak to Matthew Lauber, a consulting scientist who elaborates on the importance and challenges of biotherapeutic protein characterization, and discusses different techniques used for charge variant analysis.
Read More
Can We Treat Mood Disorders with Pharmacological Therapeutics?
BlogClinical treatments for neurological and mood disorders like social anxiety disorder and major depressive disorder have failed to show consistent efficacy in treating patients. VistaGen Therapeutics is aiming to correct that. We talked to VistaGen’s CEO, Shawn Singh, about the need for treatments in this area and why Vistagen thinks their compounds AV-101 and PH94B could be promising therapies.
Read More
Hybridoma vs Phage Display for Monoclonal Antibody Production
BlogThis blog highlights the key advantages and drawbacks of hybridoma development and phage display for a monoclonal antibody production in order to help you determine the best method for your needs.
Read More
